Atrial fibrillation is common among patients with kidney failure treated with hemodialysis. A recent study published in AJKD by Winkelmayer et al examined the efficacy and safety of apixaban for atrial fibrillation in patients on dialysis.

AJKDBlog’s Interviews Editor Timothy Yau chatted with author Wolfgang C. Winkelmayer about the clinical conundrum of both increased stroke and increased bleeding risk in patients on dialysis and how this affects the decision to anticoagulate. They review the results of his most recent findings and discuss ongoing research in this field.

If the embedded player above doesn’t work, please click here to watch the video interview. Special thanks to Dr. Winkelmayer for his time and insight!

To view this Original Investigation by Winkelmayer et al [subscription required], please visit AJKD.org:

Title: Effectiveness and Safety of Apixaban Initiation Following Newly-Diagnosed Atrial Fibrillation in Patients With Kidney Failure on Hemodialysis
Authors: Wolfgang C. Winkelmayer, Kevin F. Erickson, Pascale Khairallah, Mingyue He, Maria E. Montez-Rath, Tara I. Chang
DOI: 10.1053/j.ajkd.2025.10.009